Clinical Trials at Banner Sun Health Research Institute  

Ongoing Clinical Trials

research  

We have more than 25 studies, and there are usually 10 open for enrollment at any time.

We have many trials and studies, but most commonly we conduct:

Below is a list of some of our ongoing clinical trials. To get more information about clinical trials, please call (623) 832-6500. Other trials can also be found online at Centerwatch.com.

 

 

Parkinson's Disease Trials


Parkinson’s Progressive Marker Initiative PPMI

This study will collect clinical information, samples of blood, DNA, urine, cerebral spinal fluid, and brain images from subjects with Parkinson's Disease (PD) and from subjects without PD. This information will be used to help develop biomarkers for PD. Biomarkers are measures that tell something about PD. This study is looking at biomarkers in PD because they may help to understand how the disease changes over time. Having good biomarkers for PD may also be useful in developing new treatments and may help to improve clinical care in the future. In this study we will test biomarkers that may be related to the way PD changes over time.

To qualify: Age 18 and above with or without PD.


Kyowa

This study will test the safety and effectiveness of the investigational research study drug,  to determine if it can reduce OFF time for Parkinson’s disease patients with motor fluctuations and dyskinesia.

To qualify:  Age 30 and older with a diagnosis of Parkinson’s disease.


PSG-3

The purpose of this study is to determine if an investigational drug  is safe and helpful in slowing the rate of Parkinson’s disease.

To qualify: Age 30 and older with a diagnosis of Parkinson’s disease.


Adamas 301
 
This study is being conducted to evaluate the safety, effectiveness and tolerability of the study medication for the  treatment of Levodopa induced dyskinesia or involuntary movements  involving the head, body, and limbs that are typically associated with Parkinson’s disease.

To qualify: Age of 30-85 with a diagnosis of Parkinson’s disease.

 

 

Alzheimer's studies


Takeda

This research study has two goals.The first goal is to see if it is possible to predict if a person will develop Mild Cognitive Impairment (MCI: a brain disorder where thinking abilities are mildly impaired) due to Alzheimer’s Disease (AD) based on a method that uses a person’s genetic status and age.

The second goal of this study is to test a medicine called AD-4833, which is low-dose pioglitazone, to see if it will delay the first symptoms of MCI due to AD in people who are currently cognitively (thinking, reasoning and memory) normal and thought to be at high risk for developing this condition (based on their investigational results).

To qualify: Age of 65-83 with no history or complaint of memory problems.


ADCS A4 LZAZ

The Anti-Amyloid Treatment in Asymptomatic Alzheimer’s study (the “A4 study”) is a clinical trial for older individuals who may be at risk for Alzheimer’s disease memory loss.

The A4 study is testing an anti-amyloid investigational drug in older individuals who have evidence of elevated amyloid build-up in their brains, but who do not show symptoms of AD in order to slow possible AD-related damage in the brain and to delay progression of AD-related memory loss.

The purpose of this study is to test whether an investigational drug  can slow the progression of memory problems associated with brain amyloid.

To qualify: Age of 65-83 with no history of or complaint of memory problems.


Genentech Marguerite ROAD study (Roche)

The purpose of this study is to test an investigational drug in people with Mild to Moderate Alzheimer’s disease.

To qualify: Age of 50-90 with a diagnosis of Mild to Moderate Alzheimer’s disease.


Neuronix

Research study about Alzheimer's disease and the effect of cognitive training sessions along with Transcranial Magnetic Stimulation (TMS). TMS is a non-invasive procedure that uses a magnetic field to cause activity in the brain. The magnetic field is produced by a coil that is held next to your scalp.

To qualify: Age of  60-90 with a diagnosis of Mild to Moderate Alzheimer’s disease.


Lilly LZAX

The primary purpose of your participation in this study is to help answer the following research questions, and not to provide you treatment for your condition.

• Whether an investigational medication will slow mental and functional decline in mild AD.

To qualify: Age of 55-90 with a diagnosis of mild Alzheimer’s disease.


Merck 8931 

The purpose of the study is to:

  • Test the safety and how well a person tolerates two doses of the research study drug MK-8931 in subjects with Amnestic Mild Cognitive Impairment (aMCI) due to Alzheimer's Disease (AD).
  • Assess the effect of two doses of MK 8931 on disease progression (disease getting worse) in subjects with aMCI due to AD.

To qualify: Age of 50-85 diagnosed with Mild Cognitive Impairment and no diagnosis of Alzheimer’s disease.


Avid 1451 A05

The purpose of this study is to compare PET images of an investigational imaging agent in subjects with Mild Cognitive Impairment, other forms of Cognitive Impairment. This study will assess if there is an increase in tau protein in the brain over time, measured by the PET scan. The safety of the investigational agent is also being tested.

To qualify:  Age of 50 and above diagnosed with Mild Cognitive Impairment or other cognitive Impairments.  No diagnosis of Alzheimer’s disease.


Navidea 02 histopathology

The purpose of this study is to evaluate the safety of an investigational imaging agent to see how well the agent works in the detection of beta amyloid deposits in the brain based on the images made during life and then compared to results of a brain during autopsy after death.
Beta amyloid deposits are always present in the brains of people with Alzheimer’s disease, but might also be present in the brains of people who do not have Alzheimer’s disease.  In other words, people who do not have beta amyloid deposits do not have Alzheimer’s disease.  Sometimes people who do have beta amyloid deposits have Alzheimer’s disease at the time the image is made, and sometimes they do not.

To qualify: Age 21 and above diagnosed with a medical condition with approximate life expectancy of 6 months.

 

Enroll in a trial
Banner Sun Health Research Institute
10515 W. Santa Fe Drive
Sun City, AZ 85351
(623) 832-6500
 
 
 
Jump to top links